Board Compensation - Jiangxi Rimag Group Co., Ltd. reported total compensation for board members for the fiscal year ending December 31, 2024, amounting to RMB 1,420,000[5] - The total compensation for board members for the fiscal year ending December 31, 2023, was RMB 1,002,000, indicating an increase of approximately 42% year-over-year[6] - The company has not paid any fees, bonuses, allowances, or other remuneration to the board members for their roles as supervisors for both fiscal years 2023 and 2024[6] Governance Structure - The board of directors includes both executive and non-executive members, ensuring a diverse governance structure[7] - The chairman and CEO, Mr. Chen Chaoyang, leads the board, emphasizing strong leadership in corporate governance[7] Financial Transparency - The company is committed to transparency in its financial disclosures, as evidenced by the supplementary announcement regarding board member compensation[4] - Jiangxi Rimag Group Co., Ltd. continues to prioritize the accuracy and completeness of its financial reporting to stakeholders[1] - The company is focused on maintaining compliance with listing rules and regulations, as highlighted in its supplementary announcements[4] Future Reporting - Jiangxi Rimag Group Co., Ltd. is preparing its annual report for the fiscal year ending December 31, 2024, which will provide further insights into its financial performance and strategic direction[3] Board Composition Changes - The company has made changes in its board composition, with new appointments and resignations noted in the recent announcements[5][6]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江西一脈陽光集團股份有限公司 呈交日期： 2025年5月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

Summary of Key Points Core Viewpoint - On May 27, 36 Hong Kong-listed companies conducted share buybacks totaling 25.22 million shares, with a total buyback amount of 1.047 billion HKD [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 979,000 shares for 500 million HKD, with a highest price of 514.000 HKD and a lowest price of 507.000 HKD, bringing its total buyback amount for the year to 24.53 billion HKD [1][2]. - Meituan-W repurchased 3.02 million shares for 392 million HKD, with a highest price of 132.400 HKD and a lowest price of 122.600 HKD, totaling 392 million HKD in buybacks for the year [1][2]. - China COSCO Shipping repurchased 6.17 million shares for 89.84 million HKD, with a highest price of 14.820 HKD and a lowest price of 14.280 HKD, accumulating 4.41 billion HKD in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on May 27 was from Tencent Holdings at 500 million HKD, followed by Meituan-W at 392 million HKD [1][2]. - In terms of buyback volume, China COSCO Shipping led with 6.17 million shares, followed by NetEase Technology and Meituan-W with 5 million shares and 3.02 million shares, respectively [1][2]. Group 3: First-Time Buybacks - Notably, Meituan-W and Zhongxu Future conducted their first buybacks of the year on this date [2].

表格類別： 股票 狀態： 新提交 公司名稱： 江西一脈陽光集團股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 呈交日期： 2025年5月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔 ...

Core Viewpoint - The company, Yipai Yangguang, is redefining the third-party medical imaging industry in China through an innovative "shared model," establishing a strong competitive moat and entering a high-growth phase with synchronized revenue and profit increases [3][11]. Group 1: Company Strategy and Operations - Yipai Yangguang has built a comprehensive service system centered on medical imaging, with over 100 imaging centers across the country, serving more than 500 institutions and achieving an annual scanning volume of tens of millions [4][5]. - The company is focusing on a "CDH model" that integrates consumer (C), doctor (D), and healthcare institution (H) services, enhancing operational efficiency and creating a health community ecosystem [6][7]. - The company is exploring new operational models for flagship imaging centers to transform perceived "loss-making strategic resources" into operational advantages [5][7]. Group 2: Market Expansion and Internationalization - Yipai Yangguang is expanding internationally, leveraging its cost-effective hardware and advanced data services to penetrate markets in Hong Kong, Macau, Southeast Asia, the Middle East, and Africa [8][10]. - The establishment of the "Yipai Medical Health Technology Alliance" with Hong Kong Medical Health aims to create a dual-engine supply chain platform for global distribution [9]. - The company is utilizing its mature data services to replace local systems in overseas markets, enhancing efficiency and reducing costs significantly [10][11]. Group 3: Future Growth and Industry Positioning - The company emphasizes the importance of data in enhancing traditional medical services, positioning itself as a leader in the evolving medical imaging landscape [11][12]. - Yipai Yangguang's strategic focus on maintaining value with existing hospital partners and leveraging standardized professional modules is expected to sustain its competitive edge [7][11]. - The company’s ability to convert strategic insights into financial performance is a key factor attracting continued investment [4][11].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 若股份曾以超過一個每股價格發行/出售/購回/贖回，則須提供每股成交量加權平均價格。 公司名稱： 江西一脈陽光集團股份有限公司 呈交日期： 2025年5月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 ( ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年5月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包 ...

Investment Rating - The report assigns an "Outperform" rating to the company for the first time, with a target price range of HKD 20.76 to 25.62, indicating a potential upside of 10.1% to 35.8% compared to the current stock price of HKD 18.86 [4][6]. Core Insights - The company is a leading player in the domestic medical imaging service sector, leveraging AI to enhance the value of imaging data. Despite facing revenue pressure in 2024, the long-term growth potential remains strong due to the expected expansion of third-party imaging services and the overall market growth [2][4][55]. - The company operates 106 imaging centers across 16 provinces in China, providing a comprehensive range of services that include imaging center services, imaging solution services, and cloud services [3][20][26]. - The medical imaging service market in China is projected to grow significantly, with a CAGR exceeding 30% from 2023 to 2030, driven by increasing demand and supportive policies for independent imaging centers [2][37]. Summary by Sections Financial Performance - In 2024, the company is expected to generate revenue of HKD 761 million, a decline of 18.1% year-on-year, with a net profit of -HKD 46 million, marking a shift from profit to loss [4][9][85]. - The gross margin for 2024 is projected at 36.5%, an increase of 0.7 percentage points, attributed to higher-margin differentiated imaging solutions and improved cost control [11][82]. Business Model and Strategy - The company has established a three-part service capability: imaging center services, imaging solution services, and cloud services, aiming to create a multi-layered, full-cycle medical imaging ecosystem [3][26][68]. - The company plans to expand its international business and has formed a joint venture to explore medical technology supply chain platforms [68][75]. Market Potential - The third-party medical imaging service market in China is still in its early stages, with a penetration rate of only about 1% as of 2023, compared to the more mature U.S. market [2][37][42]. - The report highlights the significant growth potential for third-party imaging centers, with the market expected to reach HKD 186 billion by 2030 [2][37]. Future Projections - Revenue forecasts for 2025 to 2027 are HKD 997 million, HKD 1.227 billion, and HKD 1.477 billion, respectively, with expected growth rates of 31.1%, 23.1%, and 20.3% [4][85]. - The company anticipates returning to profitability in 2025, with net profits projected at HKD 49 million, HKD 81 million, and HKD 113 million for the following years [4][85].

Group 1 - Company Yanguang Health Management is acquiring an 18.0% stake in Shanghai Ronggong Company from Fanghou No.1 [1] - The company will also subscribe for an additional 9.58% stake in Shanghai Ronggong through a capital increase agreement, with a total investment of RMB 12.72 million [1] - Following the completion of the capital increase, Yanguang Health Management will hold a total of 25.9% of Shanghai Ronggong [1] Group 2 - Yanguang Health Management is purchasing a 51.0% stake in Wuhan Ronggong for RMB 5.1 million, which will make Wuhan Ronggong a subsidiary of the company [2] - Shanghai Ronggong focuses on providing innovative financial technology solutions in the medical industry through its self-developed SaaS platform [2] - Wuhan Ronggong is involved in the wholesale and retail of various medical devices and has a significant market presence in the medical supply chain [2] Group 3 - The company aims to become a diversified imaging service provider for the entire medical imaging industry chain [3] - The strategic integration with Shanghai Ronggong and Wuhan Ronggong is expected to enhance the company's reach and create more business opportunities [3] - The acquisitions will enrich the company's financial tools and business models, promoting innovative solutions in imaging services [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 關連交易 (1) 訂立有關上海融公社的增資協議；及 (2) 自上海融公社收購武漢融公社51%股權 背景 茲提述本公司日期為2024年11月1日及2024年11月21日的公告，內容有關一脈陽 光健康管理（本公司一間全資附屬公司）向芳侯一號收購上海融公社18.0%的股權 的關連交易。 董事會欣然宣佈，於2025年5月23日（交易時段前），一脈陽光健康管理、上海 融公社、芳侯一號、芳侯投資、芳侯二號、武漢卓爾及彭盈松就一脈陽光健康 管理認購上海融公社9.58%的股權訂立增資協議。 背景 茲提述本公司日期為2024年11月1日及2024年11月21日的公告，內容有關一脈陽 光健康管理（本公司一間全資附屬公司）向芳侯一號收購上海融公社18.0%的股權 的關連 ...